TAXUS III. In May 2002, we announced the final results from our TAXUS III trial. TAXUS III was a single-arm registry examining the feasibility of implanting up to two paclitaxel-eluting stents for the treatment of in-stent restenosis. The trial enrolled 29 patients. This group represents patients with complex vascular disease having recurrent occlusion in a stent. The trial’s main focus was safety, and the primary endpoint was 30-day MACE. The trial confirmed safety and reported no stent thromboses, no deaths, and an in-stent restenosis rate of 4 percent.